Sign in with your email address username.


[Correspondence] Mortality risk with dual antiplatelet therapy?

The dual antiplatelet therapy (DAPT) study1 identified a significant reduction in ischaemic cardiovascular events with prolonged thienopyridine use on a background of aspirin therapy. An unexpectedly high mortality rate was seen among patients treated with drug-eluting stents who were randomly allocated to receive continued thienopyridine compared with placebo (2·0% vs 1·5%, p=0·05). Because of the crucial role that these medications have in treatment of cardiovascular disease, these findings prompted appropriate attention.